Humacyte, Inc. Increase (Decrease) in Accounts Payable
Humacyte, Inc. (HUMA) reported Increase (Decrease) in Accounts Payable of -$1.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-12
- Humacyte, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$912.00K, a 161.04% decline year-over-year.
- Humacyte, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$362.00K, a 155.44% decline year-over-year.
- Humacyte, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$4.16M.
- Humacyte, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $2.99M, a 168.37% increase year-over-year.
- Humacyte, Inc. increase (decrease) in accounts payable for fiscal 2025 was $973.00K.
- Humacyte, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$1.96M, a 140.78% decline from fiscal 2023.
- Humacyte, Inc. increase (decrease) in accounts payable for fiscal 2023 was $4.81M.
- Humacyte, Inc. increase (decrease) in accounts payable for fiscal 2022 was -$509.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 6 month as first filed | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$912.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$1.27M 10-Q · filed 2026-08-12 | -$5.43M derived: sum of 3 quarters · filed 2026-08-12 | -$2.45M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | -$362.00K 10-Q · filed 2026-05-13 | -$4.52M derived: sum of 2 quarters · filed 2026-05-13 | -$1.54M derived: sum of 3 quarters · filed 2026-05-13 | -$42.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | -$4.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$1.17M derived: sum of 2 quarters · filed 2026-03-27 | $320.00K derived: sum of 3 quarters · filed 2026-08-12 | $973.00K 10-K · filed 2026-03-27 | |
| 2025-09-30 | $2.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $4.48M derived: sum of 2 quarters · filed 2026-08-12 | $5.13M 10-Q · filed 2025-11-12 | $2.70M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $1.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.15M 10-Q · filed 2026-08-12 | -$290.00K derived: sum of 3 quarters · filed 2026-08-12 | $823.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $653.00K 10-Q · filed 2026-05-13 | -$1.78M derived: sum of 2 quarters · filed 2026-05-13 | -$671.00K derived: sum of 3 quarters · filed 2026-05-13 | $1.64M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$1.32M derived: sum of 2 quarters · filed 2026-03-27 | $987.00K derived: sum of 3 quarters · filed 2026-03-27 | -$1.96M 10-K · filed 2026-03-27 | |
| 2024-09-30 | $1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.42M derived: sum of 2 quarters · filed 2025-11-12 | $475.00K 10-Q · filed 2025-11-12 | $3.99M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $2.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$638.00K 10-Q · filed 2025-08-11 | $2.88M derived: sum of 3 quarters · filed 2025-08-11 | $3.41M derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | -$2.95M 10-Q · filed 2025-05-13 | $570.00K derived: sum of 2 quarters · filed 2025-05-13 | $1.10M derived: sum of 3 quarters · filed 2025-05-13 | $1.56M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $3.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $4.04M derived: sum of 2 quarters · filed 2025-03-31 | $4.51M derived: sum of 3 quarters · filed 2025-03-31 | $4.81M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $526.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $993.00K derived: sum of 2 quarters · filed 2024-11-08 | $1.29M 10-Q · filed 2024-11-08 | -$201.00K derived: sum of 4 quarters · filed 2024-11-08 | |
| 2023-06-30 | $467.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $766.00K 10-Q · filed 2024-08-13 | -$727.00K derived: sum of 3 quarters · filed 2024-08-13 | -$117.00K derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $299.00K 10-Q · filed 2024-05-13 | -$1.19M derived: sum of 2 quarters · filed 2024-05-13 | -$584.00K derived: sum of 3 quarters · filed 2024-05-13 | -$1.14M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | -$1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$883.00K derived: sum of 2 quarters · filed 2024-03-28 | -$1.44M derived: sum of 3 quarters · filed 2024-03-28 | -$509.00K 10-K · filed 2024-03-28 | |
| 2022-09-30 | $610.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $50.00K derived: sum of 2 quarters · filed 2023-11-09 | $984.00K 10-Q · filed 2023-11-09 | $30.00K derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$560.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $374.00K 10-Q · filed 2023-08-14 | -$580.00K derived: sum of 3 quarters · filed 2023-08-14 | -$592.00K derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $934.00K 10-Q · filed 2023-05-12 | -$20.00K derived: sum of 2 quarters · filed 2023-05-12 | -$32.00K derived: sum of 3 quarters · filed 2023-05-12 | $142.00K derived: sum of 4 quarters · filed 2023-05-12 | |
| 2021-12-31 | -$954.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$966.00K derived: sum of 2 quarters · filed 2023-03-24 | -$792.00K derived: sum of 3 quarters · filed 2023-03-24 | -$197.00K 10-K · filed 2023-03-24 | |
| 2021-09-30 | -$12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $162.00K derived: sum of 2 quarters · filed 2022-11-10 | $757.00K 10-Q · filed 2022-11-10 | $734.94K derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $174.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $769.00K 10-Q · filed 2022-08-12 | $1.36K 10-Q · filed 2021-08-16 | $746.94K derived: sum of 3 quarters · filed 2022-08-12 | $774.00K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $595.00K 10-Q · filed 2022-05-13 | $572.94K derived: sum of 2 quarters · filed 2022-05-13 | $600.00K derived: sum of 3 quarters · filed 2022-05-13 | ||
| 2020-12-31 | -$22.06K derived: 10-K/A 6 month − 10-Q 3 month · filed 2021-05-14 | $5.00K 10-K/A · filed 2021-05-14 | -$889.00K 10-K · filed 2022-03-29 | ||
| 2020-09-30 | $27.06K 10-Q · filed 2020-11-13 | $539.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |